Abstract
Retrospective studies and meta-analysis suggest that UPTR confers a survival benefit in patients with asymptomatic unresectable mCRC undergoing chemotherapy, however a consensus of its role in routine clinical practice in the current era of targeted therapies is lacking. This study aimed to analyse the survival benefit of UPTR in the context of tumour location and mutational status in patients receiving chemotherapy and targeted therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
